Natixis Advisors LLC Boosts Stock Holdings in Enovis Co. (NYSE:ENOV)

Natixis Advisors LLC increased its holdings in Enovis Co. (NYSE:ENOV - Free Report) by 52.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,381 shares of the company's stock after purchasing an additional 6,701 shares during the period. Natixis Advisors LLC's holdings in Enovis were worth $850,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. UMB Bank n.a. increased its holdings in shares of Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after purchasing an additional 437 shares during the last quarter. Pinnacle Bancorp Inc. grew its holdings in Enovis by 54.5% during the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock valued at $37,000 after buying an additional 300 shares in the last quarter. FMR LLC increased its stake in Enovis by 20.5% in the 3rd quarter. FMR LLC now owns 2,840 shares of the company's stock worth $122,000 after acquiring an additional 484 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Enovis during the 3rd quarter worth approximately $217,000. Finally, Legacy Capital Wealth Partners LLC bought a new position in shares of Enovis during the 4th quarter valued at approximately $228,000. 98.45% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reduced their price target on shares of Enovis from $65.00 to $64.00 and set a "buy" rating on the stock in a research report on Thursday, February 27th.

Enovis Trading Down 2.9 %

NYSE ENOV traded down $1.14 during trading hours on Friday, hitting $37.74. 479,654 shares of the company were exchanged, compared to its average volume of 706,157. The stock has a market cap of $2.15 billion, a PE ratio of -17.23 and a beta of 2.05. Enovis Co. has a 52 week low of $35.14 and a 52 week high of $62.79. The stock has a 50-day moving average price of $42.06 and a 200 day moving average price of $43.35. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.06. The company had revenue of $560.98 million for the quarter, compared to analyst estimates of $555.14 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. Analysts forecast that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.